A cost-effectiveness analysis of intensive therapy of type 2 diabetes mellitus (results of Steno-2 study)
Intensive combined therapy including modification of the lifestyle, intake of metformin and/or sulfonylureas, insulin treatment in the absence ofadequate HbAc1 control, hypolipidemic, early antihypertensive and antithrombotic therapy not only decreases the frequency of DM2 complicationsbut also redu...
Saved in:
| Main Authors: | Yury Shavkatovich Khalimov, Alla Vsevolodovna Rudakova |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Endocrinology Research Centre
2011-06-01
|
| Series: | Сахарный диабет |
| Subjects: | |
| Online Access: | https://www.dia-endojournals.ru/jour/article/view/5647 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Results of the ADVANCE trial and interventional observational program ADVANCE-ON: whether our understanding of the relationship of glycemic factors and the risk of vascular complications in patients with type 2 diabetes has changed?
by: Marina Vladimirovna Shestakova, et al.
Published: (2015-12-01) -
The place of gliclazide MB in modern treatment strategies for patients with type 2 diabetes mellitus
by: N. A. Petunina, et al.
Published: (2024-09-01) -
Pharmacoeconomic aspects of the use of sulfonylurea drugs in type 2 diabetes mellitus
by: Alla Vsevolodovna Rudakova
Published: (2011-09-01) -
Indonesia DIA-RAMADAN Study: A Real-life, Prospective and Observational of Gliclazide MR in Type-2 Diabetes Patients During Ramadan Fasting
by: Soebagijo Adi Soelistijo, et al.
Published: (2022-04-01) -
What’s the latest on sulphonylureas in the management of type 2 diabetes?
by: Gail Mkele
Published: (2013-12-01)